CDK12 and prostate cancer: In prostate cancer, inactivation or loss of CDK12 leads to a unique genomic instability pattern characterized by widespread focal tandem duplications throughout the genome, some of which may occur in coding regions, resulting in gene fusions and potential fusion-induced neoantigens [25].